Mercer Global Advisors
PSTV

Mercer Global Advisors’s Plus Therapeutics PSTV Stock Holding History

Mercer Global Advisors’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Buy
+2,564
New +$19.4K ﹤0.01% 3205
2025
Q4 		– Sell
-1,139
Closed -$19.5K – 2950
2025
Q3 		$19.5K Buy
+1,139
New +$14K ﹤0.01% 2620

Other funds holding PSTV

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mercer Global Advisors's PSTV Position: Q1 2026 in Review

Mercer Global Advisors opened a new position in Plus Therapeutics (PSTV) in Q1 2026: 2,564 shares worth $10.4K. The stake represents ﹤0.01% of the portfolio and ranks #3205 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in PSTV as recently as Q3 2025.

Mercer Global Advisors first reported a position in PSTV in Q3 2025 and has held it in 2 quarters since. The position peaked at $19.5K in Q3 2025. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • Mercer Global Advisors held 2,564 shares of Plus Therapeutics worth $10.4K as of Q1 2026.
  • Plus Therapeutics was a new Mercer Global Advisors position in Q1 2026.
  • Plus Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3205 holding.
  • Mercer Global Advisors first reported a position in Plus Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Mercer Global Advisors's Plus Therapeutics position peaked at $19.5K in Q3 2025.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.